Lilly’s diabetes drug Trulicity hit the mark in a late-stage trial showing higher doses of the medication significantly reduced A1C from baseline versus the product’s approved once-weekly usage.
Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.
Gelesis announced that the United States Food and Drug Administration cleared the biotechnology company’s lead product candidate Plenity (Gelesis100) as an aid in weight management in adults with a Body Mass Index (BMI) of 25–40 kg/m2, when used in conjunction with diet and exercise.
A 2017 study found that more than 700 million adults and children worldwide are obese, calling it a “rising pandemic.”
Tivity Health Inc. said the company would acquire Nutrisystem Inc. in a cash-and-stock deal that values the weight management product developer at $1.4 billion.
Researchers at Flinders University in Australia – working with mice – removed a single gene known as RCAN1 and then fed them a variety of diets, including a high-fat diet. The mice did not gain weight, even after dramatically overeating high-fat foods over several weeks.
Alkermes Plc’s schizophrenia drug ALKS 3831 met the main goal of keeping in check a common side effect of antipsychotic medicines – weight gain – taking the company one step closer to a marketing approval for the experimental treatment.
Adults who have a regular bedtime are likely to weigh less than those who do not, to have lower blood sugar and to face a lower risk of heart disease and diabetes, according to a U.S. study.
Healthy adults who do not keep their LDL-C, or “bad cholesterol,” in check are more likely to die prematurely from cardiovascular disease than peers with lower cholesterol levels, a U.S. study suggests.